Table 3.

Disposition of patients in phase II/III clinical development program

	Dalbavancin	Comparator
Total treated	1778	1224
Completed study medication	1518 (85.0)	1061 (86.5)
Did not complete study medication	219 (12.3)	143 (11.7)
Treatment failure/worsening clinical status	25 (1.4)	16 (1.3)
Adverse event	49 (2.7)	31 (2.5)
Patient withdrew consent or for reason other than adverse event	21 (1.2)	19 (1.5)
Death	0 (0.0)	1 (0.1)
Patient lost to follow-up	27 (1.5)	13 (1.1)
Patient non-compliance	10 (0.6)	9 (0.7)
Withdrawn at investigator’s discretion	6 (0.3)	9 (0.7)
Other	81 (4.5)	45 (3.7)
Completed study	1595 (89.4)	1098 (89.6)
Did not complete study	190 (10.6)	127 (10.4)
Adverse event	0 (0.0)	1 (0.1)
Patient withdrew consent	42 (2.4)	22 (1.8)
Death	10 (0.6)	13 (1.1)
Patient lost to follow-up	107 (6.0)	67 (5.5)
Subject noncompliance	2 (0.1)	0 (0.0)
Prohibited concomitant medication used	1 (0.1)	0 (0.0)
Other	28 (1.6)	24 (2.0)

Data are presented as N (%)